Frank Neumann

'Can't say no': Kite Phar­ma taps Frank Neu­mann as new head of clin­i­cal de­vel­op­ment

Kite Phar­ma hit a ma­jor land­mark in Ju­ly when it got a sec­ond FDA OK, cre­at­ing the first com­mer­cial CAR-T port­fo­lio. But a biotech’s work is nev­er done. Now it’s time to ex­pand — and the Gilead sub­sidiary has tapped a new glob­al head of clin­i­cal de­vel­op­ment to lead the charge.

“Kite was al­ways kind of on the hori­zon as the… dream job come true,” Frank Neu­mann told End­points News. “This is a po­si­tion (where) if you’re in­ter­est­ed in cell ther­a­py, if you’re in­ter­est­ed in mak­ing a big im­pact on pa­tients’ lives, you just can’t say no.”

The Rheinis­che-Friedrich-Wil­helm Uni­ver­si­ty grad cut his teeth in cell ther­a­py at Take­da, where he served as glob­al head of clin­i­cal de­vel­op­ment for projects from proof-of-con­cept to Phase I eval­u­a­tion. Af­ter that, he spent about two years at blue­bird bio, then just two weeks as CMO of Ve­rastem On­col­o­gy be­fore jump­ing to Kite.

Ken Takeshi­ta

“The peo­ple at Ve­rastem, the da­ta, the sci­ence — bril­liant,” he said. But if “some­one of­fers you to fly to the moon, you’re go­ing to be­come an as­tro­naut,” he said of the de­ci­sion to leave.

Neu­mann is tak­ing over for Ken Takeshi­ta, who is leav­ing the com­pa­ny at the end of this month to pur­sue an­oth­er op­por­tu­ni­ty, Kite vague­ly an­nounced on Mon­day morn­ing.

Takeshi­ta is pass­ing the torch just be­fore the FDA is set to make a de­ci­sion on Kite’s sup­ple­men­tal BLA for three-year-old Yescar­ta in fol­lic­u­lar lym­phoma (FL) and mar­gin­al zone lym­phoma (MZL), two types of in­do­lent non-Hodgkin’s lym­phoma (iNHL). The com­pa­ny read out pos­i­tive da­ta from the Phase II ZU­MA-5 tri­al at vir­tu­al ASH 2020 to back the new in­di­ca­tion, and reg­u­la­tors have set a PDU­FA date for March 5.

“Lym­phoma — Yescar­ta, Tecar­tus — will re­main a key fo­cus,” Neu­mann said, while de­clin­ing to go in­to much de­tail on what’s com­ing down the pipeline. He pegged sol­id tu­mors (which he called the “Holy Grail”) and ad­di­tion­al hema­to­log­i­cal ma­lig­nan­cies as long-term goals.

“The fun­da­men­tal theme is, I think, bring­ing cell ther­a­py to a point where we an­swer the ques­tion: Where can we use it?” he added lat­er.

Gilead be­came an overnight CAR-T leader when it bought Kite for $12 bil­lion back in 2017, snatch­ing up Yescar­ta in the process. It nabbed a quick OK in re­lapsed or re­frac­to­ry large B-cell lym­phoma two weeks lat­er — not long af­ter No­var­tis’ Kym­ri­ah be­came the world’s first ap­proved CAR-T ther­a­py. This past Ju­ly, Kite nabbed its sec­ond ap­proval with Tecar­tus for treat­ment for re­lapsed or re­frac­to­ry man­tle cell lym­phoma.

But Kym­ri­ah makes for tough com­pe­ti­tion. Back in Au­gust, No­var­tis said it got the in­ter­im re­sults it was look­ing for from a Phase II Kym­ri­ah tri­al in fol­lic­u­lar lym­phoma, and an­nounced plans to file with the FDA in 2021.

Look­ing to get a leg up in the CAR-T bat­tle, Kite re­leased more da­ta to bol­ster Yescar­ta at ASH in De­cem­ber, in­clud­ing in­ter­im re­sults from ZU­MA-12, a Phase II study as­sess­ing Yescar­ta as a first-line treat­ment in large B-cell lym­phoma. Af­ter a sin­gle in­fu­sion, 85% of pa­tients achieved a re­sponse, in­clud­ing 74% who saw a com­plete re­sponse. And with a me­di­an fol­low-up of 9.3 months, 70% of re­sponse-evalu­able pa­tients had on­go­ing re­spons­es, ac­cord­ing to Gilead.

The com­pa­ny al­so read out long-term re­sults from its Zu­ma-1 tri­al in large B-cell lym­phoma, in which pa­tients had a me­di­an over­all sur­vival of more than two years.

Tecar­tus, on the oth­er hand, is in var­i­ous on­go­ing stud­ies for adult acute lym­phoblas­tic leukemia (ALL), pe­di­atric ALL and NHL, and chron­ic lym­pho­cyt­ic leukemia.

A pre­vi­ous ver­sion in­cor­rect­ly re­ferred to the com­pa­ny as Kite Ther­a­peu­tics. A cor­rec­tion has been made.

Un­pack­ing the Aduhelm de­ci­sion, Ver­tex's half full glass, a $525M J&J breakup, and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

By now you have surely read about the FDA’s controversial approval of Biogen’s Alzheimer’s drug and all its reverberations. But I’d still recommend checking out the meaty recap below to make sure you didn’t miss all the angles that the Endpoints team has covered. If you’d rather look ahead, look no further than our three-day virtual panels next week at BIO, where we will discuss what the new normal means for every part of the industry.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' 'Dan­ger­ous' 'Con­fus­ing' 'Dis­as­ter'

Over the years, we’ve become used to seeing a consensus emerge early in our industry polls at Endpoints News. And when we took the pulse of drug hunters on the heels of a controversial FDA approval for aducanumab this week, it became immediately apparent that the vast majority of our readers — heavily concentrated among biopharma staffers and execs — were incensed by what they had just witnessed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

Aaron Kesselheim (Scott Eisen/AP Images for AIDS Healthcare Foundation)

Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry'

A third member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has resigned in the wake of Biogen’s controversial Aduhelm approval, slamming the agency as he left and further deepening the controversy surrounding the decision.

Harvard University professor Aaron Kesselheim quit in protest Thursday afternoon, calling the Aduhelm OK “probably the worst drug approval decision in recent U.S. history.” Kesselheim follows both Joel Perlmutter, a neurologist from Washington University in St. Louis, and David Knopman, a neurologist from the Mayo Clinic, out the door.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

David Knopman (Mayo Clinic via YouTube)

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

As the fallout from the FDA’s approval of Alzheimer’s med aducanumab grows, a second member of the adcomm overseeing that drug’s review has walked away. But even with two experts now having resigned from that committee in protest, is there enough broad-level outrage to prevent another aducanumab from getting approved?

The FDA on Wednesday lost another member of its Peripheral and Central Nervous System Drugs Advisory Committee as Mayo Clinic neurologist David Knopman hit the exit over the agency’s decision to approve Biogen’s Alzheimer’s drug Aduhelm despite the committee’s near-unanimous vote against it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

FDA au­tho­rizes about 10M J&J vac­cine dos­es, trash­es 60M more from trou­bled Emer­gent plant

The FDA on Friday released about 10 million doses of J&J’s vaccine for use, and disposed of another 60 million doses that were manufactured at the now-shuttered Emergent BioSolutions facility in Baltimore where cross-contamination occurred.

The agency said it’s not yet ready to allow the Emergent plant to be included in the J&J EUA, but that may occur soon. FDA came to the decision to authorize some of the doses after reviewing facility records and quality testing results.

An ex­pen­sive watch, shell com­pa­nies and fake in­voic­es: How two Is­raeli traders tapped in­to a $100M glob­al biotech in­sid­er trad­ing ring

It appears that we have reached the end of the saga about the global insider trading ring that collectively reaped $100 million from placing “timely, profitable” trades in biotech stocks like Ariad, Pharmacyclics and Receptos.

Tomer Feingold and Dov Malnik — Israeli traders living in Switzerland — were the last out of eight to be charged as the SEC unraveled the scheme, which ran from 2013 through 2017. Together, according to a statement in March, the pair had pocketed more than $4 million.

Janet Woodcock, acting FDA commissioner, at Thursday's Senate Appropriations hearing (Bill Clark/CQ Roll Call via AP Images)

Sen­a­tors lam­bast new Alzheimer’s drug’s price but give Janet Wood­cock a free pass on the ap­proval de­ci­sion

Senate Finance Democrats took aim at Biogen’s pricey new Alzheimer’s drug on Thursday, but members on both sides of the aisle at a separate appropriations hearing didn’t question acting FDA commissioner Janet Woodcock on the approval.

“I was appalled that Biogen priced their Alzheimer’s drug approved by the FDA at $56,000 per year — I’m not going to debate whether this is effective or not, but it’s double the household median income for Michiganders over the age of 65,” Sen. Debbie Stabenow (D-MI) said at the finance hearing.

Reshma Kewalramani, Vertex CEO (BIO via YouTube)

UP­DAT­ED: Ver­tex strikes out on its lat­est big shot at a rare ge­net­ic dis­ease. But they're go­ing to keep on swing­ing

It’s been several months since Vertex culled one of its small molecules for alpha-1 antitrypsin deficiency (AATD), taking a big hit after evidence of liver damage surfaced in a key Phase II trial. Now we learned that the company has whiffed on its second shot, and there’s nothing left in the clinic to treat the rare genetic disease — but that won’t stop it from trying.

Despite avoiding the safety issues that plagued the last candidate, Vertex $VRTX is taking the axe to VX-864 after Phase II results revealed the magnitude of the drug’s response is “unlikely to translate into substantial clinical benefit.” As a result of the news, the company’s stock fell 12.5% after hours.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

FDA plans new stud­ies on ac­cel­er­at­ed ap­proval dis­clo­sures in bio­phar­ma ads

When people read biopharma companies’ websites about new drugs approved via the FDA’s accelerated pathway, like Biogen’s new Alzheimer’s drug, do they understand that these drugs may only be reasonably likely to predict clinical benefit and still require confirmatory studies?

That’s what the FDA’s Office of Prescription Drug Promotion wants to firm up as an agency analysis of direct-to-consumer websites for accelerated approval drugs previously found that only 21% of the disclosures used language directly from the label.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.